Bird Flu Drug Mass Production Technique Discovered
creepygeek writes to mention a New Scientist article detailing a new process for creating Tamiflu, an antiviral drug currently thought to be our best defense against the bird flu. From the article: "Making Tamiflu is slow, partly because shikimic is hard to get, but also because one step in the process involves a highly explosive chemical called an azide. As a result, Tamiflu can be made only in small batches of a few tens of litres at a time. But Elias Corey of Harvard University - who won a Nobel prize in 1990 for chemical synthesis - and colleagues have devised a new way to make the drug from two cheap, plentiful petrochemicals, acrylate and butadiene."
From TFA: It's too bad that our 'biggest hope' is not up to the task, as the following articles assert:
It might be better to just stock up on old-fashioned Jewish penicillin.
____
~ |rip/\/\aster /\/\onkey
-Killer bees (there was a movie on this one too)
-SARS
-AIDs (several movies)
-Terrorism
-Anthrax (related to the above)
-Small Pox coming back
-Etc.
While they're all threats, they aren't just going to all of a sudden just break out all over the place. The media loves to feed off our fears--as it sells almost as well as sex. When it explodes, THEN freak out about it, but until then enjoy life.
Read my blog posts on usability.
I have problems with these mortality figures. It's very easy to determine who died from bird flu - you have a body, death certificate, medical records, etc. It is NOT easy to work out who has had the bird flu and has survived in the general populace - not all sick people will have seen a doctor and some may not even have developed symptoms. Without doing a massive study looking for bird-flu antibodies, the mortality figures are almost certainly overblown, maybe by orders of magnitude. This applies whether we are talking about the impact on birds or on humans.
Cheers,
Toby Haynes
Anything I post is strictly my own thoughts and doesn't necessarily have anything to do with the opinions of IBM.